How Many Doses Per Vial of Tesamorelin? (Dosing Guide)

How Many Doses Per Vial of Tesamorelin? (Dosing Guide)

A single vial of tesamorelin. Typically 2mg of lyophilised peptide. Yields anywhere from 15 to 60 doses depending on prescribed dose, reconstitution volume, and injection precision. The variance isn't about product quality. It's math. Reconstitute 2mg tesamorelin with 2mL bacteriostatic water, and you've created a 1mg/mL solution. Drawing 1mL gives you one 1mg dose. Drawing 0.5mL gives you 0.5mg. The confusion arises when vial sizes vary (1mg, 2mg, 5mg), reconstitution volumes change, or prescribed doses differ from the research-standard 1mg daily. Our team has guided researchers through this exact calculation hundreds of times. The gap between precise dosing and wasted peptide comes down to three things most guides never mention: accurate syringe measurement, consistent reconstitution technique, and understanding that dose count is a function of concentration, not vial size alone.

How many doses are in a 2mg vial of tesamorelin?

A 2mg tesamorelin vial reconstituted with 2mL bacteriostatic water yields 30 doses at 1mg daily (0.1mL per dose using an insulin syringe), 60 doses at 0.5mg daily, or 15 doses at 2mg daily. The dose count depends entirely on prescribed daily dose and reconstitution volume. The vial contains a fixed 2mg of active peptide, and dilution determines concentration per millilitre.

Direct Answer: Dose Yield From Standard Tesamorelin Vials

Most researchers assume vial size directly predicts dose count. It doesn't. A 2mg vial doesn't automatically mean '20 doses' or '30 doses'. Those numbers depend on your reconstitution math. Here's what we mean: if you reconstitute 2mg tesamorelin with 1mL bacteriostatic water, you've created a 2mg/mL solution. Every 0.1mL drawn contains 0.2mg of peptide. If your protocol calls for 1mg daily, you'd draw 0.5mL per dose, yielding only four doses per vial. Reconstitute that same 2mg vial with 2mL instead, and suddenly you're drawing 0.1mL for a 0.2mg dose. Ten doses per vial at that concentration. This article covers exactly how reconstitution volume alters dose count, how to calculate doses per vial for any prescribed amount, and what preparation mistakes cause researchers to run out of peptide weeks earlier than expected.

Tesamorelin Vial Sizes and Standard Reconstitution Volumes

Tesamorelin is typically supplied as lyophilised powder in 1mg, 2mg, or 5mg vials. Though 2mg is the most common research-grade format. The lyophilised form is stable at −20°C for 24–36 months before reconstitution, but once mixed with bacteriostatic water, the peptide must be refrigerated at 2–8°C and used within 28 days. Standard reconstitution follows a 1mg peptide per 1mL bacteriostatic water ratio, yielding a 1mg/mL concentration. This simplifies dose calculation and minimises measurement error when using insulin syringes marked in 0.01mL increments.

Reconstituting a 2mg vial with 2mL bacteriostatic water creates a 1mg/mL solution. Drawing 0.1mL delivers 0.1mg of tesamorelin. Drawing 1mL delivers 1mg. If your protocol specifies 1mg daily, each vial yields exactly 20 doses (2mg total ÷ 0.1mg per dose). If the prescribed dose is 0.5mg daily, the same vial yields 40 doses. Researchers sometimes reconstitute with larger volumes. 3mL or 4mL. To create more dilute solutions for protocols requiring very small daily doses, but this increases the risk of contamination through repeated needle insertions and reduces the peptide's usable lifespan due to higher water content accelerating degradation.

Here's what most peptide suppliers won't emphasise: reconstitution volume is not arbitrary. Using too little water (e.g., 0.5mL for a 2mg vial) creates a highly concentrated 4mg/mL solution that's difficult to measure accurately with standard insulin syringes. A 0.025mL measurement error at that concentration translates to a 0.1mg dosing error, which compounds over weeks. Using too much water (e.g., 5mL for a 2mg vial) creates a 0.4mg/mL solution that requires drawing larger volumes per dose, increasing the number of times you insert a needle into the vial and raising contamination risk. The 1mg/mL standard exists because it balances measurement precision, vial lifespan, and contamination minimisation.

Calculating Dose Count Based on Prescribed Daily Amount

Dose count per vial follows a simple formula: (Total mg in vial) ÷ (Daily dose in mg) = Number of doses. A 2mg vial at 1mg daily yields two doses. At 0.5mg daily, it yields four doses. At 0.2mg daily, it yields ten doses. The complexity enters when you account for reconstitution volume, because what you're actually calculating is: (Concentration in mg/mL) × (Volume drawn in mL) = Dose delivered in mg.

Let's walk through three real-world scenarios. Scenario one: You have a 2mg vial, reconstitute with 2mL bacteriostatic water (creating 1mg/mL), and your protocol calls for 1mg daily. You draw 1mL per dose. The vial yields two doses. That's it. Scenario two: Same 2mg vial, same 2mL reconstitution (1mg/mL), but your protocol calls for 0.1mg daily. You draw 0.1mL per dose. The vial now yields 20 doses. Scenario three: You reconstitute a 5mg vial with 5mL bacteriostatic water (1mg/mL) and dose at 0.5mg daily. You draw 0.5mL per dose. That vial yields ten doses.

The most common dosing error isn't math. It's syringe precision. Insulin syringes are marked in 0.01mL increments, but accurately drawing volumes below 0.05mL requires steady hands and good lighting. Drawing 0.03mL when you intended 0.05mL represents a 40% underdose. Over a 30-day cycle, that cumulative error can result in running out of peptide a full week early or significantly underdelivering the prescribed amount. Our experience working with research teams shows that reconstitution volumes should be chosen so that daily doses fall between 0.1mL and 1mL on the syringe. This range minimises human measurement error while keeping needle insertion frequency manageable.

Tesamorelin Dosing Protocols: Research vs Clinical Standards

Research-grade tesamorelin protocols typically follow growth hormone-releasing hormone (GHRH) dosing patterns established in clinical trials for HIV-associated lipodystrophy. The FDA-approved clinical dose for tesamorelin (brand name Egrifta) is 2mg subcutaneously once daily, administered as a single injection. Research applications exploring cognitive enhancement, body composition optimisation, or metabolic function often use lower doses. 0.5mg to 1mg daily. To minimise side effects while retaining partial efficacy on growth hormone secretion.

Tesamorelin works by binding to GHRH receptors in the anterior pituitary gland, stimulating the release of endogenous growth hormone in a pulsatile pattern that mimics natural secretion. Unlike exogenous growth hormone, which suppresses natural production, tesamorelin preserves the body's feedback loop. Growth hormone levels rise during the hours following injection, then return to baseline, allowing normal pituitary function to continue. This mechanism makes dosing frequency critical: daily administration is required because tesamorelin has a half-life of approximately 26–38 minutes in plasma, meaning it's cleared rapidly and does not accumulate.

Clinical trials published in The Lancet and the Journal of Clinical Endocrinology & Metabolism used 2mg daily for 26–52 weeks and documented statistically significant reductions in visceral adipose tissue (VAT). The deep abdominal fat associated with metabolic syndrome. Without affecting subcutaneous fat or lean mass. Lower doses (0.5mg–1mg daily) are common in research contexts exploring neuroprotective effects or off-label metabolic applications, but published efficacy data at those levels is limited. Here's the honest answer: if your protocol calls for 0.5mg daily and you're using a 2mg vial reconstituted to 1mg/mL, you're drawing 0.5mL per dose. That vial yields exactly four doses, not the 30 doses you'd get at a 0.067mg daily dose (which isn't a standard protocol).

Tesamorelin Vial Dosing: Full Comparison

Key Takeaways

• A 2mg tesamorelin vial reconstituted with 2mL bacteriostatic water at 1mg/mL concentration yields dose counts ranging from 2 doses (at 1mg daily) to 20 doses (at 0.1mg daily).
• Tesamorelin has a plasma half-life of 26–38 minutes, requiring daily subcutaneous administration to maintain efficacy. Missing doses resets growth hormone pulsatility.
• Standard reconstitution follows a 1mg peptide per 1mL water ratio to balance measurement precision, contamination risk, and peptide stability within the 28-day refrigerated use window.
• Clinical trials for HIV-associated lipodystrophy used 2mg daily for 26–52 weeks, demonstrating mean visceral adipose tissue reductions of 15–18% versus placebo.
• Reconstituted tesamorelin must be stored at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible peptide degradation that neither appearance nor potency can detect.

What If: Tesamorelin Dosing Scenarios

What If I Accidentally Reconstitute With the Wrong Volume?

Recalculate your concentration immediately using (Total mg in vial) ÷ (Volume added in mL) = New concentration in mg/mL. If you added 3mL to a 2mg vial instead of 2mL, your concentration is now 0.67mg/mL instead of 1mg/mL. You'll need to draw 1.5mL to get a 1mg dose instead of 1mL. Mark the vial with the correct concentration and adjust your syringe measurements accordingly. Do not attempt to add or remove liquid after reconstitution. The peptide is already in solution and further manipulation increases contamination risk.

What If I Run Out of Peptide Before the Expected Dose Count?

This indicates either measurement error during reconstitution, drawing excess volume per dose, or loss through dead space in the syringe and needle hub. Insulin syringes retain approximately 0.02–0.04mL in the needle hub after injection. Over 20 doses, that's 0.4–0.8mL of wasted solution, equivalent to 0.4–0.8mg of peptide at 1mg/mL concentration. Switching to low-dead-space syringes reduces this waste to under 0.01mL per injection. Verify your reconstitution math and consider using a precision scale to confirm water volume before mixing.

What If My Protocol Requires a Dose That Doesn't Divide Evenly Into the Vial Size?

Choose a reconstitution volume that makes your daily dose easy to measure. If your protocol calls for 0.75mg daily from a 2mg vial, reconstitute with 2mL (1mg/mL) and draw 0.75mL per dose. The vial yields 2.67 doses, meaning you'll need a second vial mid-cycle. Alternatively, reconstitute with 2.67mL to create a 0.75mg/mL solution and draw 1mL per dose for simpler measurement. Running out mid-protocol is preferable to dosing inaccurately.

The Straightforward Truth About Tesamorelin Vial Lifespan

Here's the honest answer: most researchers waste peptide not through degradation but through poor reconstitution planning. A 2mg vial doesn't inherently yield 'X doses'. It yields whatever your math says it yields, and if you reconstitute without calculating dose volume first, you'll either run out early or overdose unintentionally. The 28-day post-reconstitution window isn't arbitrary. It's based on sterility limits for bacteriostatic water and peptide stability data showing that tesamorelin retains greater than 95% potency for four weeks at 2–8°C. Stretching a vial beyond 28 days because 'it still looks clear' increases infection risk and potency loss that you cannot visually detect. If your dose count math says the vial should last 35 days, reconstitute a smaller portion or accept that you'll discard unused solution. Using degraded peptide defeats the purpose of precision research.

Storage and Handling: Why Temperature Excursions Ruin Dose Counts

Lyophilised tesamorelin stored at −20°C remains stable for 24–36 months, but once reconstituted, the peptide's stability window collapses to 28 days under refrigeration at 2–8°C. The reason is water content. Lyophilised peptides are freeze-dried to remove moisture, which would otherwise allow hydrolysis (breakdown of peptide bonds by water molecules) and bacterial growth. Adding bacteriostatic water back reintroduces both risks, which is why reconstituted vials must be refrigerated and used within four weeks.

A single temperature excursion. Leaving the vial out at room temperature (20–25°C) for six hours. Can reduce tesamorelin potency by 10–15% through partial denaturation of the peptide structure. The damage is cumulative and irreversible: the peptide doesn't 'recover' when returned to the fridge. What researchers often miss is that denatured tesamorelin looks identical to active tesamorelin. The solution remains clear, colourless, and free of visible particles even after significant potency loss. You cannot tell by appearance whether a vial has been compromised.

Our experience working with research teams in this space shows a consistent pattern: vials stored in standard refrigerators (which cycle between 3–9°C depending on door-opening frequency) retain full potency across the 28-day window, while vials stored in mini-fridges or wine coolers (which fluctuate between 6–12°C) show measurable potency drops by day 21. Purpose-built peptide refrigerators with tighter temperature control are worth the investment if you're working with high-value compounds. The cost of replacing degraded peptide exceeds the cost of proper storage equipment within two to three cycles.

If you're exploring tesamorelin or related research peptides, Real Peptides offers high-purity, small-batch synthesised compounds with exact amino-acid sequencing. The kind of consistency that makes dose-count math reliable instead of a gamble. Our Thymalin and MK 677 products demonstrate the same precision manufacturing standards that ensure every milligram in the vial matches the label claim, so your reconstitution calculations hold up across the full 28-day use period.

Those vials aren't single-use containers. But they're not infinite either. If the peptide concerns you, calculate dose count before reconstitution and verify your math against syringe markings before the first injection. Precision at the preparation stage costs nothing extra upfront and matters across the entire research timeline.